ANNOUNCEMENTS | 08.20.2024

Universal DX (UDX) Closes Series B Funding for Clinical Trials on Colorectal Cancer Screening Blood Test, Signal-C®

Choate represented Universal DX (UDX) in IP diligence for its Series B funding round. This funding advances the clinical trial of Signal-C, UDX's colorectal cancer screening blood test, which is on track to enroll 15,000 patients across 100 sites. The funding is an extension of the $70M Series B round that UDX closed in November 2023. In addition to the IP diligence, Choate manages UDX's patent portfolio.

William R. Haulbrook, PhD
Partner

Stephanie L. Schonewald, PhD
Partner

Margo Monroe, PhD
Principal

Samuel Polio, PhD
Patent Agent

© 2026 Choate, Hall & Stewart LLP | Two International Place, Suite 3000 | Boston, MA 02110 | 617-248-5000